Neogenomics Inc
NEO12.280USD
-0.020-0.16%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
1.58BMarket Cap
LossP/E TTM
More Details of Neogenomics Inc Company
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Neogenomics Inc Info
Ticker SymbolNEO
Company nameNeogenomics Inc
IPO dateDec 10, 2012
CEOZook (Antony P)
Number of employees2200
Security typeOrdinary Share
Fiscal year-endDec 10
Address9490 Neogenomics Way
CityFORT MYERS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33912
Phone12397680600
Websitehttps://neogenomics.com/
Ticker SymbolNEO
IPO dateDec 10, 2012
CEOZook (Antony P)
Company Executives of Neogenomics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
174.72K
-6.40%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
99.50K
-8.10%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
52.34K
+30.57%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
28.10K
+77.33%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
7.16K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alison L. Hannah, M.D.
Dr. Alison L. Hannah, M.D.
Independent Director
Independent Director
--
--
Mr. Gregory Aunan
Mr. Gregory Aunan
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Alicia Olivo
Ms. Alicia Olivo
Executive Vice President, General Counsel & Business Development
Executive Vice President, General Counsel & Business Development
--
--
Mr. Michael A. Kelly
Mr. Michael A. Kelly
Lead Independent Director
Lead Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jeffrey Scott (Jeff) Sherman
Mr. Jeffrey Scott (Jeff) Sherman
Chief Financial Officer
Chief Financial Officer
174.72K
-6.40%
Mr. Warren Stone
Mr. Warren Stone
President, Chief Operating Officer
President, Chief Operating Officer
99.50K
-8.10%
Mr. Stephen Michael Kanovsky
Mr. Stephen Michael Kanovsky
Independent Director
Independent Director
52.34K
+30.57%
Dr. Neil Gunn
Dr. Neil Gunn
Independent Director
Independent Director
28.10K
+77.33%
Ms. Felicia Williams
Ms. Felicia Williams
Independent Director
Independent Director
7.16K
--
Ms. Lynn A. Tetrault, J.D.
Ms. Lynn A. Tetrault, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinical Services-Client direct billing
131.16M
72.33%
Clinical Services-Commercial Insurance
28.77M
15.86%
Clinical Services-Medicare and Medicaid
21.39M
11.79%
Clinical Services-Self-Pay
20.00K
0.01%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinical Services-Client direct billing
131.16M
72.33%
Clinical Services-Commercial Insurance
28.77M
15.86%
Clinical Services-Medicare and Medicaid
21.39M
11.79%
Clinical Services-Self-Pay
20.00K
0.01%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.72%
First Light Asset Management, LLC
7.67%
Greenhouse Funds LLLP
6.35%
Millennium Management LLC
5.01%
Other
56.65%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.59%
The Vanguard Group, Inc.
10.72%
First Light Asset Management, LLC
7.67%
Greenhouse Funds LLLP
6.35%
Millennium Management LLC
5.01%
Other
56.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.58%
Investment Advisor/Hedge Fund
29.42%
Hedge Fund
23.57%
Research Firm
2.99%
Pension Fund
1.27%
Individual Investor
1.26%
Bank and Trust
0.58%
Sovereign Wealth Fund
0.09%
Family Office
0.04%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
568
127.88M
98.83%
-9.78M
2025Q2
571
126.82M
98.17%
-12.95M
2025Q1
596
131.44M
102.13%
-4.71M
2024Q4
585
127.59M
99.32%
-7.82M
2024Q3
589
129.38M
100.96%
-8.76M
2024Q2
597
131.21M
102.74%
-9.36M
2024Q1
633
132.83M
104.04%
-13.13M
2023Q4
672
130.90M
102.70%
-12.18M
2023Q3
691
124.98M
98.00%
-16.78M
2023Q2
691
121.76M
95.45%
-23.63M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
17.77M
13.76%
-516.86K
-2.83%
Jun 30, 2025
The Vanguard Group, Inc.
14.10M
10.92%
-126.36K
-0.89%
Jun 30, 2025
First Light Asset Management, LLC
6.85M
5.3%
+803.61K
+13.30%
Jun 30, 2025
Greenhouse Funds LLLP
7.43M
5.75%
+2.72M
+57.83%
Jun 30, 2025
Millennium Management LLC
3.32M
2.57%
-3.40M
-50.63%
Jun 30, 2025
State Street Investment Management (US)
5.11M
3.96%
+21.77K
+0.43%
Jun 30, 2025
Deerfield Management Company, L.P.
2.15M
1.66%
+2.15M
--
Jun 30, 2025
Dimensional Fund Advisors, L.P.
4.29M
3.32%
+448.53K
+11.66%
Jun 30, 2025
Schroder Investment Management North America Inc.
3.72M
2.88%
-587.33K
-13.63%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
State Street SPDR S&P Health Care Services ETF
2.38%
Invesco S&P SmallCap Health Care ETF
0.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.5%
Inspire Small/Mid Cap ESG ETF
0.32%
iShares U.S. Healthcare Providers ETF
0.2%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
0.14%
iShares S&P Small-Cap 600 Value ETF
0.12%
Nuveen ESG Small-Cap ETF
0.11%
iShares ESG Select Screened S&P Small-Cap ETF
0.1%
iShares Core S&P Small-Cap ETF
0.09%
View more
State Street SPDR S&P Health Care Services ETF
Proportion2.38%
Invesco S&P SmallCap Health Care ETF
Proportion0.77%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proportion0.5%
Inspire Small/Mid Cap ESG ETF
Proportion0.32%
iShares U.S. Healthcare Providers ETF
Proportion0.2%
Invesco S&P SmallCap 600 QVM Multi-factor ETF
Proportion0.14%
iShares S&P Small-Cap 600 Value ETF
Proportion0.12%
Nuveen ESG Small-Cap ETF
Proportion0.11%
iShares ESG Select Screened S&P Small-Cap ETF
Proportion0.1%
iShares Core S&P Small-Cap ETF
Proportion0.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Neogenomics Inc?
The top five shareholders of Neogenomics Inc are:
BlackRock Institutional Trust Company, N.A. holds 17.77M shares, accounting for 13.76% of the total shares.
The Vanguard Group, Inc. holds 14.10M shares, accounting for 10.92% of the total shares.
First Light Asset Management, LLC holds 6.85M shares, accounting for 5.30% of the total shares.
Greenhouse Funds LLLP holds 7.43M shares, accounting for 5.75% of the total shares.
Millennium Management LLC holds 3.32M shares, accounting for 2.57% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 17.77M shares, accounting for 13.76% of the total shares.
The Vanguard Group, Inc. holds 14.10M shares, accounting for 10.92% of the total shares.
First Light Asset Management, LLC holds 6.85M shares, accounting for 5.30% of the total shares.
Greenhouse Funds LLLP holds 7.43M shares, accounting for 5.75% of the total shares.
Millennium Management LLC holds 3.32M shares, accounting for 2.57% of the total shares.
What are the top three shareholder types of Neogenomics Inc?
The top three shareholder types of Neogenomics Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
First Light Asset Management, LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
First Light Asset Management, LLC
How many institutions hold shares of Neogenomics Inc (NEO)?
As of 2025Q3, 568 institutions hold shares of Neogenomics Inc, with a combined market value of approximately 127.88M, accounting for 98.83% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.66%.
What is the biggest source of revenue for Neogenomics Inc?
In FY2025Q2, the Clinical Services-Client direct billing business generated the highest revenue for Neogenomics Inc, amounting to 131.16M and accounting for 72.33% of total revenue.
